Menu

Recent Interviews

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


03. November 2019 | 07:37 CET

BAYER, MERCK OR NOVARTIS - WHO BUYS NOXXON PHARMA?

  • Pharma

The therapy and cure of serious diseases is a large market with a high willingness to invest. Companies that are active in research and development need experienced teams and partners as well as a lot of liquidity and opportunities to carry out tests. Bayer, Merck and Novartis are well-known global players in the research and treatment of cancer. It is not uncommon for these companies to work with small partners and, if successful, to even acquire them. A transaction may be imminent.

time to read: 1 minutes by Mario Hose


 

FURTHER STUDIES ACCORDING TO NEW DATA

The Berlin-based biotech company NOXXON focuses on the treatment of pancreatic and colorectal cancer as well as brain tumors. Based on the published, updated data from the clinical NOX-A12 study in metastatic, microsatellite-stable patients with pancreatic or colorectal cancer in September 2019, NOXXON believes that further clinical studies in these indications are justified.

The development can be described as a successful development. In the next step, the company aims to find industry partners to provide anti-PD1 therapy and financial support to conduct a study.

SIGNIFICANT ADVANCES IN NOX-A12

"The near final data from the NOX-A12 study in combination with immunotherapy in patients with metastatic, microsatellite-stable pancreatic or colorectal cancer and the start of another NOX-A12 study in combination with radiotherapy in the first-line treatment of brain tumor patients are significant advances in the clinical development of NOX-A12 for NOXXON. We are still in discussions with potential partners to enter into agreements to share the financial risks associated with the further development of our cancer therapies," said Aram Mangasarian, Chief Executive Officer of NOXXON.

PHASE 1/2 STUDY HAS STARTED

NOXXON has started the phase 1/2 study with NOX-A12 in combination with radiotherapy. According to the company, patients with inoperable brain tumors (glioblastoma) for whom biomarker analysis confirms that they do not benefit from standard chemotherapy will be treated.

If the data from this study show positive results, the company will discuss the most efficient development path for this indication with the relevant authorities in a Scientific Advice, taking into account orphan drug status in the US and Europe.

ACQUISITION CAN OFFER TIME ADVANTAGE

NOXXON's goal is to identify industry partners for the combination of NOX-A12 with radiotherapy to fund further clinical trials in brain tumors and other indications where radiotherapy is the key component of standard therapy.

NOXXON expects that at least preliminary top-line clinical data from this study will be required to enter into a partnership in this area. The advantage of acquiring NOXXON for a major player is that it will gain a head start in a market worth billions. The coming weeks will be exciting.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.